Compare Amgen, Inc. (AMGN) vs eBay Inc (EBAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs eBay Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while eBay Inc trades at $116.78 (market cap $52.04B). The key difference: Amgen, Inc. is far larger — about 3.8× eBay Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | EBAY | |
|---|---|---|
Market Cap | $196.12B | $52.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $118.96 |
52-Week Low | $271.18 | $76.79 |
Enterprise Value | $241.41B | $55.38B |
Dividend Yield | 2.77% | 1.06% |
Volume | — | 5,186,418 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EBAY trades at $117.20, down 0.11% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.66 beating expectations of $1.58, and maintains healthy profitability with 71.79% gross margins and 17.61% net income margin. Recent news highlights GameStop's ongoing takeover interest, creating significant market attention.
EBAY presents a mixed investment case with strong operational performance offset by takeover uncertainty. The stock trades above analyst consensus target of $109.56, suggesting limited near-term upside, while the potential acquisition creates both opportunity and execution risk. Key risks include competitive pressures in e-commerce and integration challenges from recent acquisitions like Depop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
